pharmaphorum

APRIL 19, 2022

EHDS is the first data space devised to promote health-data exchange and support research on new treatments, preventative strategies, medicines, and medical devices while aiming to allow individuals the right to control their personal health data. The post The largest pharma company in Europe calls for interoperability appeared first on.

Pharma Companies 111

Pharma Companies Life Science Clinical Research Research 111

Outsourcing Pharma

DECEMBER 12, 2023

Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimerâs Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.

Pharma Companies 83

Pharma Companies Medicine Development Regulation 83

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Still, navigating such patent issues during drug development can be difficult, and Camargo can assist in finding a safe course. Ken Phelps.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

JUNE 15, 2023

Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money. Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Food and Drug Administration approval.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

pharmaphorum

NOVEMBER 26, 2020

Marketing agency VMLY&R has launched a new global healthcare agency, VMLY&Rx, to service specialty prescription pharmaceutical companies developing innovative breakthrough therapies. The post VMLY&R creates global healthcare agency for innovative pharma companies appeared first on.

Pharma Companies 52

Pharma Companies Branding Marketing Development 52

Delveinsight

JULY 21, 2021

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease.

Pharma Companies 94

Pharma Companies Marketing Insulin Development 94

XTalks

OCTOBER 4, 2023

But we have a group of products in areas such as oncology, specialized medicine and cell and gene therapies, where traditional frameworks for drug reimbursement decision-making pose challenges both for manufacturers of innovative medicines and for drug reimbursement decision-makers. And there are a couple of reasons for that.

Marketing 105

Marketing Development Drugs Gene Therapy 105

Pharmaceutical Technology

JANUARY 16, 2023

Recent cases in the pharmaceutical sector include Poolbeg Pharma finding more than one respiratory syncytial virus (RSV) vaccine candidate with AI by going through a vast amount of early stage clinical data to prioritise candidates and reposition them as novel treatments for RSV infection.

Big Data 303

Big Data Pharma Companies Clinical Trials Clinical Trials 303

Delveinsight

SEPTEMBER 24, 2021

Pharma companies such as Calliditas Therapeutics AB, Chinook Therapeutics, Inc., Further, the IgAN market is also observing a lot of collaborations and partnerships to jointly develop and commercialize therapies, which shows an active interest of pharma and biotech companies in the domain.

Pharma Companies 77

Pharma Companies Marketing Protein Drugs 77

pharmaphorum

APRIL 19, 2021

But it has also faced criticism from pharma companies that say it undervalues medicines – patients in the country were denied access to the expensive cystic fibrosis drug Orkambi for four years because of a pricing row with NICE and the NHS.

Medicine 88

Medicine Pharma Companies Genome Genomics 88

Camargo

MARCH 9, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency.

Development 146

Development Manufacturing Drugs Production 146

pharmaphorum

NOVEMBER 5, 2020

Talking Medicines has raised £1.1 million) in funding that will be used to develop an artificial intelligence (AI) data platform that can be used by pharma companies to gain insights into how patients perceive them. To date Talking Medicines has raised £2.5 million ($1.4

Medicine 59

Medicine Pharma Companies Branding Regulation 59

Pharmaceutical Technology

FEBRUARY 24, 2023

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Regulation 162

Regulation Clinical Trials Clinical Trials Medicine 162

The Pharma Data

JANUARY 24, 2021

–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

STAT News

FEBRUARY 13, 2023

Sanofi’s head of research and development, John Reed, is leaving the pharmaceutical giant to pursue a new opportunity, the company announced Monday. Reed joined Sanofi in 2018, after holding a similar position at Swiss pharma company Roche. and a leading researcher in cell biology.

Life Science 98

Life Science Pharma Companies Medicine Research 98

pharmaphorum

DECEMBER 21, 2021

During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals. The potential to leverage genomic data.

Development 98

Development Genome Genomics Drugs 98

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is where partners such as Abacus Medicine Pharma Services can really help,” says Simon Estcourt, managing director of Abacus Medicine Pharma Services. There are many reasons why a company might prefer to keep commercialisation activities inhouse. De-risking drug launch.

Drugs 130

Drugs Pharma Companies Sales Production 130

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. developed dementia over the subsequent two years (vs. Notably, among over-65s who had had Covid-19, 4.5%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Fossil Remedies

JULY 15, 2022

As the number of people affected by these problems is increasing, there is a high demand for medicines required to treat them. If you are planning to launch Cardiac Diabetic PCD Pharma Franchise, then it is the best time. You need an ISO-confirmed company that has WHO and GMP certification also.

Pharma Companies 52

Pharma Companies Packaging Packaging Medicine 52

Drug Discovery World

OCTOBER 6, 2022

This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. With key players including AstraZeneca, Bayer, Novartis and Pfizer pushing the boundaries of drug development, the reason behind this growth is evident. Valued at $14.8 until 2030. References: .

Development 52

Development Drugs Life Science Marketing 52

pharmaphorum

APRIL 12, 2022

Under the model, the NHS in England will pay a fixed annual fee for access to the two medicines of £10 million per year, calculated based on the value they offer the health service, regardless of how much is used to treat patients. Pfizer and Shionogi submitted the drugs for consideration in the scheme when it was first announced in 2019.

Pharma Companies 119

Pharma Companies Development Drugs Medicine 119

Pharmaceutical Technology

JUNE 30, 2022

While private pharma companies also take part in such efforts, their efforts has largely been limited to donating assets or distributing treatments. Covid-19 strained development and treatment efforts. However, some big pharma players have a history of donating some treatments to the cause, he explains.

Pharma Companies 162

Pharma Companies FDA Approval Development Drugs 162

Drug Discovery World

FEBRUARY 5, 2024

One-third (32%) of rare disease patients are not aware they can access unlicensed medicines through Early Access Programmes, new research has revealed. However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

pharmaphorum

APRIL 8, 2021

COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . BioNTech seeks “new kind of pharma company”.

Development 93

Development Drugs Vaccination Vaccine 93

World of DTC Marketing

APRIL 14, 2021

BMS believes they price our medicines based on the value they deliver,” but physicians say the price is too high. One of the biggest problems with a system that directs medical research towards profits rather than needs is that R&D funding is channelled to those products that can make pharma companies the most money.

Pharma Companies 191

Pharma Companies Vaccination Vaccine Sales 191

pharmaphorum

OCTOBER 28, 2020

Claus Møldrup explores research showing that patients want their voice to be heard more by pharma, and asks what a truly effective feedback loop for medicines might look like. Pharma remains stubbornly closed to feedback, with potentially damaging consequences for the industry, healthcare systems and patients.

Medicine 119

Medicine Pharma Companies Vaccination Vaccine 119

World of DTC Marketing

JANUARY 4, 2022

However, several gaps in our current understanding of this problem limit the development of highly effective solutions. According to a team of Penn State College of Medicine researchers, care for the 15 most prevalent types of cancer in the U.S. National costs for cancer care were estimated to be $190.2 billion in 2015 and $208.9

Pharma Companies 273

Pharma Companies Drugs Medicine Research 273

pharmaphorum

MAY 20, 2022

Several of the top pharmaceutical companies have joined a new coalition that aims to improve access to cancer medicines in low- and lower-middle-income countries (LLMICs). It is taking a broader approach, making sure patients living with cancer “receive the medicines they need at the right time,” he said.

Drugs 111

Drugs Medicine Licensing Licensing 111

Pharmaceutical Technology

JULY 21, 2022

In 2010, only eight big pharma companies had an access strategy for low- and middle-income countries, but today, 17 of the biggest 20 companies do. In response to the Ukraine crisis, many pharma companies are ensuring a supply of essential medicine to Ukraine and surrounding countries.

Pharma Companies 130

Pharma Companies Clinical Trials Clinical Trials Drugs 130

World of DTC Marketing

JANUARY 24, 2022

Venture capitalists have poured $42 billion into drug development over the past three years. Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? billion, which was much lower than previous studies, which have placed the average cost of drug development as $2.8

Life Science 225

Life Science Drugs Genetic Disease Development 225

World of DTC Marketing

MARCH 11, 2022

consumers’ trust in pharma is low, despite the industry’s contributions to ending the pandemic: Only 15% of U.S. consumers say they trust pharma companies more than they did before the COVID-19 pandemic, according to Accenture’s 2021 survey. What does this mean for DTC and HCP marketing?

Pharma Companies 212

Pharma Companies Vaccination Vaccine Doctors 212

Pharmaceutical Technology

MAY 17, 2023

However, Randy Burkholder, vice president of policy and research for the industry group Pharmaceutical Research and Manufacturers of America (PhRMA), said this provision amounted to government “price setting” that would harm future research and development efforts.

Insulin 130

Insulin Drugs Pharma Companies Manufacturing 130

pharmaphorum

DECEMBER 15, 2021

Going from the vital activity of patient engagement to the more encompassing state of patient centricity requires big steps in the evolution of new-drug discovery, development, and delivery. It is drug developers, patients, advocates, and caregivers in active conversations—more likely to involve clean sheets of paper than prepared scripts.

Pharma Companies 145

Pharma Companies Development Medicine Clinical Trials 145

pharmaphorum

JULY 8, 2022

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Drugs 131

Drugs Clinical Development Marketing Genome 131

Drug Discovery World

SEPTEMBER 15, 2023

Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development.

Drugs 52

Drugs RNA Pharma Companies Vaccination 52

pharmaphorum

NOVEMBER 29, 2021

.” It says the interested parties include UK biotech Oxford BioMedica, Swiss chemicals group Lonza, and Japan’s Fujifilm, which has subsidiaries that provide contract development and manufacturing services to the pharma industry.

Vaccination 105

Vaccination Vaccine Manufacturing Pharma Companies 105

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 119

Licensing Licensing Marketing Medicine 119